Collagen, the stuff of ligaments and skin, and the most abundant protein in the human body, has an extraordinary role in triggering chemical signals that help protect the body from cancer, a new study has revealed.
In contemporary practice, medical oncologists use novel anticancer agents on-label more often than off-label.
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year’s most significant developments in cancer.
Use of the oral antidiabetes drug metformin improved survival in women with ovarian cancer, according to the findings of a retrospective case-control study.
Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.
Inhibiting one protein eliminated metastasis of melanoma in lab studies, a finding that could lead to targeted therapies for a range of cancers.
The ability to detect cancer DNA in the blood has been combined with genome sequencing technology in a test that could be used to screen for cancers, monitor cancer patients for recurrence, and find residual cancer left after surgery.
Excessive levels of interleukin-15 initiate large granular lymphocyte (LGL) leukemia, but also represent a promising therapeutic target.
The mTOR inhibitor dramatically reduced the volume of subependymal giant cell astrocytomas (SEGAs) in persons with tuberous sclerosis complex.
Gemtuzumab ozogamicin, discontinued here in 2010, reduced relapse risk and improved survival in Welsh patients with acute myeloid leukemia.
